Eton Pharmaceuticals (ETON) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ETON's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA ma…

ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.…

Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product …

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript…

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.…

Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully d…

Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% i…

DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…

Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.…

DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…

Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The …

DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based…

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.…

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

Eton Pharmaceuticals, Inc. (NASDAQ: ETON - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. Two investment …

Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission…

BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833…

Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Co…

Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The inst…

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

